These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 27936119)

  • 1. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
    Bissonnette R; Maari C; Barber K; Lynde CW; Vender R
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1576-81. PubMed ID: 25600828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.
    Manriquez J; Alsina-Gibert M
    Clin Exp Dermatol; 2017 Jan; 42(1):14-20. PubMed ID: 27943384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
    Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
    Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
    Kyriakou A; Patsatsi A; Sotiriadis D
    J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
    Tan E; Baker C; Foley P
    Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study.
    De Simone C; Caldarola G; Maiorino A; Tassone F; Campana I; Sollena P; Peris K
    Dermatol Ther; 2016 Sep; 29(5):372-376. PubMed ID: 27146358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-α antagonist treatment using a novel interleukin-8 reporter cell line.
    Kimura Y; Shimada-Omori R; Takahashi T; Tsuchiyama K; Kusakari Y; Yamasaki K; Nishikawa R; Nishigori C; Aiba S
    Br J Dermatol; 2016 Nov; 175(5):979-987. PubMed ID: 27155194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept.
    Gyldenløve M; Zachariae C; Jensen P; Griehsel H; Ståhle M; Skov L
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e518-e519. PubMed ID: 28557009
    [No Abstract]   [Full Text] [Related]  

  • 16. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study.
    Pinheiro RR; Duarte B; Ferreira A; Cabete J
    Eur J Dermatol; 2018 Feb; 28(1):89-91. PubMed ID: 29400282
    [No Abstract]   [Full Text] [Related]  

  • 18. Antidrug antibodies in psoriasis: a systematic review.
    Hsu L; Snodgrass BT; Armstrong AW
    Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
    Engin B; Tanakol A; Bulut H; Songür A; Vehid HE; Gökalp E; Kutlubay Z; Özkoca D; Tüzün Y; Serdaroğlu S
    Int J Dermatol; 2020 Feb; 59(2):207-215. PubMed ID: 31531981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.